Principia Biopharma reported the appointment of Patrick Machado to its Board of Directors. According to a media release, Machado brings operating experience, including his time as a co-founder, chief business officer and chief financial officer of Medivation Inc., where he provided strong leadership in the development of XTANDI and its successful commercial launch in prostate cancer. He also served as a member of Medivation's Board of Directors until its acquisition by Pfizer in 2016.